Ribociclib (Kisqali®). Also known as Kisqali® (Novartis, Basel, Switzerland), this compound is a highly specific inhibitor of CDKs 4/6 that received FDA approval for use in the upfront treatment of hormone receptor-positive (HR+), HER2-negative breast cancer in 2017 [858]. This evidence concerns the gene ERBB2 and breast carcinoma.